Comprehending COVID-19: Preliminary Examination of the SARS-CoV-2 Spike Protein by Peptide Mapping

Significance of the topic

The SARS-CoV-2 spike glycoprotein mediates virus entry into host cells and is densely glycosylated, directly influencing immune recognition and vaccine efficacy. Detailed mapping of its primary sequence and glycan modifications is crucial for rational design and quality control of protein-based COVID-19 vaccine candidates.

Objectives and Study Overview

This work presents a preliminary peptide mapping study of a recombinant SARS-CoV-2 spike protein expressed in HEK293 cells. The aims were to confirm the amino acid sequence, characterize N- and O-glycosylation sites, and demonstrate a streamlined LC-MS workflow suitable for vaccine development and QC analyses.

Methodology and Instrumentation

A tryptic digestion protocol was applied to denatured, reduced, and alkylated spike protein, with and without PNGase F treatment for N-glycan removal. Peptide mixtures were analyzed on a BioAccord LC-MS System equipped with an ACQUITY UPLC Peptide BEH C18 column operated at 65 °C. Mobile phases were 0.1% formic acid in water and acetonitrile at 0.25 mL/min. Electrospray ionization in positive mode (m/z 50–2000) was used, with data acquired under high-energy MS fragmentation. Data processing and peptide assignment were performed in the UNIFI Scientific Information System.

Main Results and Discussion

• Sequence Coverage: Approximately 90 % of the spike protein sequence was confirmed by peptide mapping, both with and without N-glycan removal.
• Glycosite Assignment: Over 90 % of reported N-glycosylation and O-glycosylation sites were identified. PNGase F treatment facilitated site-specific glycan assignments.
• N234 Glycopeptide: High-confidence identification of an oligomannose-type glycan at N234, implicated in receptor-binding site shielding.
• O-Glycosylation: Confirmation of a glycan at T323, agreeing with recent literature.

Benefits and Practical Applications

This peptide mapping workflow enables robust primary sequence confirmation and monitoring of post-translational modifications (glycosylation, oxidation, deamidation) throughout process development. Its streamlined operation and integrated data analysis support accelerated vaccine candidate characterization and regulatory compliance.

Future Trends and Potential Applications

Expanding enzymatic strategies beyond trypsin, such as chymotrypsin or Glu-C, will improve coverage of challenging regions. Advances in glycoproteomics methodologies and informatics will facilitate deeper glycoform profiling. Integration with real-time process analytics and automated reporting can further streamline biopharmaceutical manufacturing and QC.

Conclusion

The BioAccord LC-MS peptide mapping approach delivered high sequence coverage and reliable glycosite assignments for the SARS-CoV-2 spike protein. Its ease of use and reproducibility make it a valuable tool for accelerating vaccine development and ensuring product consistency.

References

1. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281‐292.e6.
2. Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020;eabb9983.
3. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450‐452.
4. Shajahan A, Supekar NT, Gleinich AS, Azadi P. Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology. 2020;cwaa042.